Pierre Fabre names new CEO

7 May 2018
pierre-fabre-medicament-logo-big

French independent pharma company Pierre Fabre has named Eric Ducournau as its new chief executive, taking over from Bertrand Parmentier who has announced his retirement. The new CEO will assume his position on July 2, 2018, to allow for a smooth hand-over between the two men.

This appointment was decided by Pierre Fabre Participations - the group’s holding company, chaired by Pierre-Yves Revol - which is responsible for appointing its top executives. This decision was approved by the Pierre Fabre SA board of directors.

Mr Ducournau, aged 50, has served as CEO of Pierre Fabre Dermo-Cosmetics since his appointment by Mr Pierre Fabre in October 2012, prior to which, he held positions of increasing responsibility since joining the company in 2000. After heading the President Office from 2000 to 2005, he was named group secretary-general from 2006 to 2011, handling duties including group legal affairs and market access for the pharmaceuticals branch. In 2011, he was appointed group deputy managing director, assuming the additional responsibilities of heading quality, regulatory affairs, and pharmacovigilance.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical